[go: up one dir, main page]

GT200300043A - BETA3 ADRENERGIC RECEIVER AGONISTS - Google Patents

BETA3 ADRENERGIC RECEIVER AGONISTS

Info

Publication number
GT200300043A
GT200300043A GT200300043A GT200300043A GT200300043A GT 200300043 A GT200300043 A GT 200300043A GT 200300043 A GT200300043 A GT 200300043A GT 200300043 A GT200300043 A GT 200300043A GT 200300043 A GT200300043 A GT 200300043A
Authority
GT
Guatemala
Prior art keywords
beta3 adrenergic
receiver agonists
agonists
adrenergic receiver
beta3
Prior art date
Application number
GT200300043A
Other languages
Spanish (es)
Inventor
Jenniffer Anne Lafontaine
Bradley Paul Morgan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of GT200300043A publication Critical patent/GT200300043A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA GENERAL I EN DONDE R1,R2,R3,R4,R5,R6,R7,R8,R9,AR, X,M,HET, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS DISMINUYEN DE FORMA EFICAZ LOS NIVELES SANGUINEOS DE GLUCOSA CUANDO SE ADMINISTRAN POR VIA ORAL ADEMAS DE REDUCIR EL PESO CORPORAL O DISMINUYENDO LA GANANCIA DE PESO.THE PRESENT INVENTION CONCERNS COMPOUNDS OF GENERAL FORMULA I WHERE R1, R2, R3, R4, R5, R6, R7, R8, R9, AR, X, M, HET, ARE FUNCTIONAL GROUPS DESCRIBED IN THE RECORD. THESE COMPOUNDS EFFECTIVELY DECREASE THE BLOOD LEVELS OF GLUCOSE WHEN IT IS ADMINISTERED ORALWAY IN ADDITION TO REDUCING THE BODY WEIGHT OR DECREASING THE WEIGHT GAIN.

GT200300043A 2002-02-27 2003-02-26 BETA3 ADRENERGIC RECEIVER AGONISTS GT200300043A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36025102P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
GT200300043A true GT200300043A (en) 2003-09-22

Family

ID=27766207

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300043A GT200300043A (en) 2002-02-27 2003-02-26 BETA3 ADRENERGIC RECEIVER AGONISTS

Country Status (13)

Country Link
EP (1) EP1485379A1 (en)
JP (1) JP2005518448A (en)
AU (1) AU2003248356A1 (en)
BR (1) BR0308070A (en)
CA (1) CA2476316A1 (en)
DO (1) DOP2003000587A (en)
GT (1) GT200300043A (en)
MX (1) MXPA04007127A (en)
PA (1) PA8567701A1 (en)
PE (1) PE20030943A1 (en)
TW (1) TW200408637A (en)
UY (1) UY27680A1 (en)
WO (1) WO2003072572A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002303427A1 (en) 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
GB0324654D0 (en) * 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
KR101071748B1 (en) * 2003-12-23 2011-10-11 아스텔라스세이야쿠 가부시키가이샤 Aminoalcohol derivatives
DE102004021779A1 (en) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, process for their preparation and their use as medicines
JP5173190B2 (en) 2004-08-25 2013-03-27 武田薬品工業株式会社 Preventive and therapeutic agent for stress urinary incontinence and screening method thereof
PE20091825A1 (en) 2008-04-04 2009-12-04 Merck & Co Inc HYDROXIMETHYL PYRROLIDINES AS AGONISTS OF THE BETA 3 ADRENERGIC RECEPTOR
EP2770996B1 (en) 2011-10-27 2016-09-28 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
ES2584427T3 (en) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Process for the preparation of beta 3 agonists and intermediate products
HUE045260T2 (en) 2013-03-15 2019-12-30 Merck Sharp & Dohme A process for the production of beta 3 antagonists and their intermediates
CN117695287A (en) 2017-06-06 2024-03-15 住友制药(苏州)有限公司 Treatment of overactive bladder with velbegron
JP2022510084A (en) 2018-12-05 2022-01-26 ウロバント サイエンシズ ゲーエムベーハー Use of Viveglon to treat overactive bladder symptoms in men with benign prostatic hyperplasia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179246C (en) * 1991-11-20 1996-09-04 Sankyo Co Aromatic amino-alcohol derivatives and intermediates for their preparation
ES2181772T3 (en) * 1994-04-08 2003-03-01 Sumitomo Chemical Co COMPOUND OF ETER, ITS USE AND INTERMEDIARY FOR THE OBTAINING OF THIS COMPOUND.
US5977124A (en) * 1995-05-10 1999-11-02 Pfizer Inc. β-adrenergic agonists
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
EE200300191A (en) * 2000-10-20 2003-10-15 Pfizer Products Inc. Alpha-aryl-ethanolamines and their use as beta-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
DOP2003000587A (en) 2003-08-30
AU2003248356A1 (en) 2003-09-09
TW200408637A (en) 2004-06-01
MXPA04007127A (en) 2005-07-05
PE20030943A1 (en) 2003-11-08
UY27680A1 (en) 2003-10-31
EP1485379A1 (en) 2004-12-15
PA8567701A1 (en) 2003-11-12
CA2476316A1 (en) 2003-09-04
WO2003072572A8 (en) 2004-01-29
WO2003072572A1 (en) 2003-09-04
BR0308070A (en) 2004-12-21
JP2005518448A (en) 2005-06-23

Similar Documents

Publication Publication Date Title
GT200300043A (en) BETA3 ADRENERGIC RECEIVER AGONISTS
PE20060625A1 (en) BENZAZEPINE DERIVATIVES AS ANTAGONISTS AND / OR AGONISTS OF THE HISTAMINE H3 RECEPTOR
GT200100146A (en) ACTIVITIES OF GLUCOQUINASE ACETAMIDE BENZENICA REPLACED WITH ALFA-ACILO AND ALFA-HETEROATOMO ATOMS.
NI200300053A (en) USEFUL TROPANO DERIVATIVES IN THERAPY.
PE20081467A1 (en) BENZOYL AMINO HETEROCYCLIC COMPOUNDS AS MEDIATORS OF GLUCOKINASES (GLK)
PE20070115A1 (en) DERIVATIVES OF [1,3,5] -TRIAZINE AS INHIBITORS OF ASPARTILE PROTEASES
PE20060599A1 (en) PYRAZOLE- [3,4-d] -PYRIMIDINE DERIVATIVES AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY
PE20071322A1 (en) DERIVATIVES OF 2-MORPHOLINOPYRIMIDINE AS INHIBITORS OF PHOSPHATIDINOINOSITOL (PI) 3-KINASE
PA8581401A1 (en) IMEDAZOPIRIDINE COMPOUNDS AS 5-HT4 RECEIVER AGONISTS
PE20060777A1 (en) INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
PE20120031A1 (en) ARYL METHYL BENZOQUINAZOLINONE COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF THE M1 RECEPTOR
PE20091371A1 (en) HSP90 INHIBITORS
PE20060691A1 (en) SERINAMIDES REPLACED BY BENZOYL
HRP20090593T1 (en) Benzimidazole derivative and its use as aii receptor antagonist
GT200200122A (en) IMIDAZOTRIAZINAS
PE20070136A1 (en) COMPOUNDS DERIVED FROM N- (PYRIDIN-2-IL) -SULFONAMIDE AS INHIBITORS OF THE ENZYME 11-beta-HYDROXIESTEROID DEHIDROGENASE HUMAN TYPE 1
PA8614301A1 (en) DERIVATIVES OF TROPANO
GT200100148A (en) DERIVATIVES OF 4-PHENYL-PYRIDINE.
PE20090042A1 (en) CYCLOPAMINE ANALOGS
PE20030471A1 (en) IMIDAZOPIRIDIN COMPOUND AS 5-HT4 RECEIVER MODULATORS
CR8759A (en) 3-AMINOCICLOPENTANOCARBOXAMIDS AS MODULATORS OF CHEMIOKIN RECEPTORS
AR079550A1 (en) PIRAZOL DERIVATIVES
ECSP088966A (en) MUSCARINIC RECEIVER AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA
PE20141169A1 (en) ETHINYL DERIVATIVES
PE20081665A1 (en) RAPID DISSOCIATION DOPAMINE 2 RECEPTOR ANTAGONISTS